Scott B Hoyt
Overview
Explore the profile of Scott B Hoyt including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
229
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hoyt S, Finocchio C, Croll E, Tawa G, Li H, Ma L, et al.
ACS Med Chem Lett
. 2024 Nov;
15(11):1843-1851.
PMID: 39563805
We report the discovery of an imidazopyridine series of IRAK1/4/pan-FLT3 kinase inhibitors. Optimization of this series has produced compound which displays potent and selective inhibition of IRAK1, IRAK4, FLT3, and...
2.
Bennett J, Ishikawa C, Agarwal P, Yeung J, Sampson A, Uible E, et al.
Blood
. 2023 May;
142(11):989-1007.
PMID: 37172199
Dysregulation of innate immune signaling is a hallmark of hematologic malignancies. Recent therapeutic efforts to subvert aberrant innate immune signaling in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) have...
3.
Jones L, Melgar K, Bolanos L, Hueneman K, Walker M, Jiang J, et al.
J Clin Invest
. 2020 Mar;
130(4):2017-2023.
PMID: 32149729
Tyrosine kinase domain (TKD) mutations contribute to acquired resistance to FMS-like tyrosine kinase 3 (FLT3) inhibitors used to treat FLT3-mutant acute myeloid leukemia (AML). We report a cocrystal structure of...
4.
Melgar K, Walker M, Jones L, Bolanos L, Hueneman K, Wunderlich M, et al.
Sci Transl Med
. 2019 Sep;
11(508).
PMID: 31484791
Targeted inhibitors to oncogenic kinases demonstrate encouraging clinical responses early in the treatment course; however, most patients will relapse because of target-dependent mechanisms that mitigate enzyme-inhibitor binding or through target-independent...
5.
Hoyt S, Taylor J, London C, Ali A, Ujjainwalla F, Tata J, et al.
Bioorg Med Chem Lett
. 2017 Apr;
27(11):2384-2388.
PMID: 28416132
We report the discovery and hit-to-lead optimization of a structurally novel indazole series of CYP11B2 inhibitors. Benchmark compound 34 from this series displays potent inhibition of CYP11B2, high selectivity versus...
6.
Petrilli W, Hoyt S, London C, McMasters D, Verras A, Struthers M, et al.
ACS Med Chem Lett
. 2017 Jan;
8(1):128-132.
PMID: 28105288
Herein we report the discovery and hit-to-lead optimization of a series of spirocyclic piperidine aldosterone synthase (CYP11B2) inhibitors. Compounds from this series display potent CYP11B2 inhibition, good selectivity versus related...
7.
Whitehead B, Lo M, Ali A, Park M, Hoyt S, Xiong Y, et al.
Bioorg Med Chem Lett
. 2016 Dec;
27(2):143-146.
PMID: 27979595
The inhibition of aldosterone synthase (CYP11B2) may be an effective treatment of hypertension and heart failure, among other ailments. Previously reported benzimidazole CYP11B2 inhibitors led the way for bioisosteric imidazopyridines...
8.
Hoyt S, Petrilli W, London C, Liang G, Tata J, Hu Q, et al.
ACS Med Chem Lett
. 2015 Aug;
6(8):861-5.
PMID: 26288685
Hit-to-lead efforts resulted in the discovery of compound 19, a potent CYP11B2 inhibitor that displays high selectivity vs related CYPs, good pharmacokinetic properties in rat and rhesus, and lead-like physical...
9.
Hoyt S, Park M, London C, Xiong Y, Tata J, Bennett D, et al.
ACS Med Chem Lett
. 2015 May;
6(5):573-8.
PMID: 26005536
We report the discovery of a benzimidazole series of CYP11B2 inhibitors. Hit-to-lead and lead optimization studies identified compounds such as 32, which displays potent CYP11B2 inhibition, high selectivity versus related...
10.
Hoyt S, London C, Abbadie C, Felix J, Garcia M, Jochnowitz N, et al.
Bioorg Med Chem Lett
. 2013 May;
23(12):3640-5.
PMID: 23652221
A series of benzazepinones were synthesized and evaluated for block of Nav1.7 sodium channels. Compound 30 from this series displayed potent channel block, good selectivity versus other targets, and dose-dependent...